Opinion: The medical-billing AI arms race between providers and insurance

Key Takeaways

• CMS’s Interoperability and Prior Authorization final rule (CMS-0057-F) requires impacted payers to field FHIR Prior Authorization APIs beginning January 1, 2027.
• CMS estimated about $15 billion in ten-year savings from streamlining prior authorization and related data exchange when the rule was finalized.
• The WISeR model runs from January 1, 2026 to December 31, 2031 in six states, testing AI/ML-supported medical necessity review for selected Original Medicare services.
• Pharma access teams should treat payer AI denial engines and provider AI appeal engines as infrastructure risk to time-to-therapy, not as back-office trivia.

What does CMS require on prior authorization APIs?

According to the CMS fact sheet on CMS-0057-F, Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and QHP issuers on Federally Facilitated Exchanges must implement FHIR-based APIs that improve data exchange and prior authorization.

Prior Authorization APIs must be populated with lists of covered items and services that require authorization, identify documentation needs, and support request/response exchange. They must communicate whether a request is approved (and when authorization ends), denied (with a specific reason), or needs more information. CMS set API implementation timing beginning January 1, 2027 after stakeholder feedback delayed earlier deadlines.

How fast must payers decide?

CMS materials describing the final rule’s prior authorization process reforms include decision-time expectations that industry has treated as operational benchmarks: standard prior authorization decisions within seven calendar days and expedited decisions within 72 hours for covered processes under the rule’s framework. Payers must also publicly report annual metrics such as approval, denial, and appeal-related rates.

Those clocks matter because AI systems on both sides of the claim will optimize to them. Insurers can auto-triage documentation gaps in seconds; providers can auto-assemble packets that meet checklist criteria. The competitive equilibrium is not “human vs. robot” but “whose model better maps to payer rules.”

What is WISeR adding in Original Medicare?

The CMS WISeR (Wasteful and Inappropriate Service Reduction) model runs six performance years from January 1, 2026 through December 31, 2031 in six states, including New Jersey among the listed jurisdictions. It tests enhanced technology — including artificial intelligence and machine learning paired with clinician review — to reduce low-value services in Original Medicare fee-for-service.

• Providers may voluntarily submit prior authorization for selected services to a model participant or MAC.
• If they skip prior authorization, claims can face pre-payment medical review.
• Model participants are paid in part based on averted expenditures, aligning vendor incentives with utilization reduction.

CMS has separately framed wasteful medical spending as a large share of U.S. health outlays and highlighted Medicare’s scale — nearly one quarter of national health spending, on the order of $1 trillion in 2023 in model background materials — as rationale for technology-enabled review.

Where does pharmaceutical access get hit?

Even when drugs themselves are carved out of some medical prior-authorization API scopes, specialty therapies still depend on the same providers, billing platforms, and utilization-management vendors. When hospitals divert staff to win an AI documentation arms race, infusion scheduling and benefits verification slow. When payers deploy models that flag “low-value” adjacent procedures, oncology and rare-disease pathways can pick up collateral friction.

CMS’s press release on the final rule estimated roughly $15 billion in savings over ten years from more efficient electronic prior authorization and interoperability. Savings for taxpayers are not automatic wins for manufacturers: faster electronic denials can arrive as quickly as faster approvals.

What remains unproven?

CMS has not published a definitive scoreboard showing which commercial “AI billing” vendors win the arms race, nor proven that WISeR will reduce total cost of care without shifting burden onto complex patients. Peer-opinion claims that insurers already “own” the AI high ground should be treated as narrative until paired with transparent denial and appeal metrics the new rule requires payers to post.

Related NovaPharma coverage

• Sepsis AI algorithms need real-time data, not hindsight
• HFMA conference: affordability focus, unclear fixes
• AI citation gap in CDMO capacity

Frequently Asked Questions

Primary Sources

1. CMS fact sheet: Interoperability and Prior Authorization Final Rule CMS-0057-F
2. CMS: WISeR Wasteful and Inappropriate Service Reduction Model
3. CMS press release: Final rule on health information and prior authorization